Printer Friendly

Organogenesis begins clinical trial of living skin replacement to promote wound healing.

Organogenesis, Inc., Canton, MA, announced it has begun a clinical study of Vitrix, its living dermal replacement designed to promote wound healing in deep diabetic foot ulcers. The company says Vitrix cellular dermal replacement involves living human dermal cells, known as firbroblasts, and the dermal structural protein collagen. Vitrix can be folded and inserted into deep wounds like those caused by diabetic ulcers.

The clinical study will administer Vitrix to 20 patients with diabetic foot ulcers. If the ulcers to not health within 12 weeks, the patients will receive Organogenesis' lead product Apligraf to complete the healing process. The company says Apligraf differs from Vitrix in that it is an actual cellular skin substitute consisting of living human epidermal cells, called keratinocytes, along with the dermal cells and collagen present in Vitrix.

About 800,000 people worldwide suffer from diabetic foot ulcers, which are responsible for 50,000 amputations a year.

Contact: (617) 575-0775; Web site: www.organogenesis.com
COPYRIGHT 2001 Transplant Communications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2001 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Comment:Organogenesis begins clinical trial of living skin replacement to promote wound healing.
Publication:Transplant News
Article Type:Brief Article
Geographic Code:1USA
Date:Aug 30, 2001
Words:159
Previous Article:Thoratec submits IDE to FDA to expand number of patients in trial of its LVAS system.
Next Article:Isotechnika says its experimental immunosuppressent drug to be administered in kidney transplant patient.
Topics:


Related Articles
Novartis given approval by FDA to market Apligraf for the treatment of venous leg ulcers
FDA approves Novartis' Apligraf for treatment of diabetic foot ulcers.
BIOMARIN GETS POSITIVE DATA FROM VIBRILASE PHASE 1B TRIAL.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |